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Abstract
Background: Low back pain is a common and costly condition internationally. There is high need to identify
effective and economically efficient means for managing this problem. This study aimed to explore the
cost-effectiveness of a novel motion-sensor biofeedback treatment approach in addition to guidelines-based
care compared to guidelines-based care alone, from a societal perspective over a 12 month time horizon.
Method: This was an incremental cost-effectiveness analysis conducted concurrently with a pilot, cluster randomized
controlled trial. Health care resource use was collected using daily diaries and patient-self report at 3, 6 and 12 month
follow-up assessments. Productivity was measured using industry classifications and participant self-reporting of ability
to do their normal work with their present pain. Clinical effect was measured using the Patient Global Impression
of Change measured at the 12 month follow-up assessment. Data were compared between groups using linear
regression clustered by recruitment site. Bootstrap resampling was used to generate a visual representation of
the 95% confidence interval for the incremental cost-effectiveness estimate. Two, one-way sensitivity analyses
were undertaken to examine the robustness of findings to key assumptions.
Result: There were n = 38 participants in the intervention group who completed the 12 month assessment and
n = 45 in the control. The intervention group had greater use of trial-related medical and therapy resources [$477 per
participant (95% CI: $447, $508)], but lower use of non-trial medical and therapy resources [$-53 per participant
(95% CI: $-105, $-0)], and a greater improvement in productivity [$-5123 per participant (95% CI: $-10,174, $-72)].
Overall, the intervention dominated with a saving of $478,100 and an additional 41 participants self-rating as
being very or much improved compared to the control. There was >99% confidence in this finding of dominance in
both the primary and sensitivity analyses.
Conclusions: The motion-sensor biofeedback treatment approach in addition to guidelines- based care appears to be
both more clinically effective and economically efficient than guidelines- based care alone. This approach appears to be
a viable means to manage low back pain and further research in this area should be a priority.
Trial registration: The randomised trial this research was based upon was prospectively registered on March 25th
2009 with the Australian New Zealand Clinical Trials Registry: ACTRN12609000157279.
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Background
Low back pain presents a tremendous cost to developed
nations internationally [1]. These costs can be incurred
by patients directly, and by society as a whole through
increased use of publicly subsidized health services and
reduced paid occupational activity [2]. Loss of productivity
(in both paid and unpaid occupations) has been identified
as a key driver of these costs [3]. There is need to under-
stand how this burden of disease can be minimised.
There are many interventions that have been argued
as being beneficial for management of low back pain.
Some approaches, such as spinal surgery, come at sub-
stantial cost to patients and/or health care providers.
Other options, such as physical therapy, are less costly
to deliver but the comparative cost-effectiveness of these
approaches remains relatively unknown [4]. In the ab-
sence of robust evidence demonstrating the relative cost
effectiveness of different treatment options, clinicians
are left only with evidence examining the effectiveness
of different treatments to guide their selection. There
are conflicting results present in this literature and best
practice guidelines now make somewhat generic recom-
mendations regarding evaluation and management ap-
proaches for clinicians treating low back pain patients
[5–7]. A review of the cost-effectiveness of these ap-
proaches has identified that interdisciplinary rehabilitation,
exercise, acupuncture, spinal manipulation and cognitive-
behavioural therapy may all be cost-effective for manage-
ment of sub-acute or chronic low back pain [8].
Recent advances in technology have permitted devel-
opment of new approaches to manage low back pain.
One such approach has been the use of a motion-sensor
biofeedback systems. Biofeedback has been used for the
management of low back pain as far back as the 1980’s
with some promising short-term results [9]. These inter-
ventions however were largely restricted to laboratory
settings as the equipment was not readily portable. Re-
cent advances in the portability of this technology now
allow patients to understand how their low back moves,
and have their posture monitored while performing
everyday activities so that clinicians can receive a detailed
log of how the patient moved during the day and/or night.
Using the data from the ambulatory monitoring session,
the device can be personalised to notify or remind patients
of optimal movements and postures based on their own
condition. A recent multicentre, cluster-randomised,
placebo-controlled, pilot clinical trial reported a signifi-
cant and sustained improvement in pain and activity
limitation that persisted several months after the initial
biofeedback treatment sessions were completed using
this technology [10].
Adoption of new technologies in clinical practice should
be driven by evidence of both efficacy and of economic
efficiency [11]. There has been much recent comment
on the spiralling costs of health care being driven, in
part, by the increasing costs of service provision attribut-
able to new technologies [12]. No economic evaluation of
the use of modern motion-sensor biofeedback systems for
the management of low back pain has previously been
presented in the literature. However, the value of adding
this treatment approach to conventional, guidelines based
care needs to be established. This study aimed to explore
the cost-effectiveness of a novel motion-sensor biofeed-
back treatment approach in addition to guidelines-based
care compared to guidelines-based care alone, from a soci-
etal perspective over a 12 month time horizon.
Methods
Design
Incremental cost-effectiveness study conducted concur-
rently with a pilot, cluster randomised trial. The cluster
randomised trial included eight recruiting sites rando-
mised to either an intervention group consisting of
motion-sensor biofeedback combined with “guidelines-
based care” or a “guidelines-based care” only control
group. Further details of this trial can be found in the trial
report paper [10]. This economic evaluation took a soci-
etal perspective over a 12 month follow-up time horizon
from the date of commencing participation in the trial.
Participants and setting
This trial was conducted across eight sites (two hospitals,
six outpatient primary care clinics) in Victoria, Australia.
The participating clinicians were two physicians, four GPs
and three physiotherapists, all with a special interest in
musculoskeletal conditions. The medical practitioners had
an average of 25.8 years post-graduate experience and the
physiotherapists 19.0 years.
Patients approached for inclusion into this study
needed to be aged between 18 and 65 years, have a pri-
mary complaint of low back pain or back-related leg
pain, have an average pain intensity of three or more on
a 0–10 scale, and an episode duration of at least 3 weeks.
Patients were excluded from this study if they had sur-
gery or another invasive procedure on their lumbar
spine within the previous 12 months, if they were preg-
nant, had severe hearing impairment, had an implanted
electrical medical device, had a known allergic skin reac-
tion to tapes and plasters or any of a range of comorbid
disorders including: neoplasm, infection, inflammatory
or neurological disorder, fracture or other joint or
medically-related disorders. The flow of participants is
presented (Fig. 1).
Randomisation
This was a cluster randomised trial where clinics were
the unit of randomisation. Consequently, clinicians at
each clinic delivered only one type of treatment. Patient
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recruitment occurred from each clinician’s usual patient
flow and clinicians were not blind to treatment alloca-
tion. Randomisation was undertaken by allocating each
of the three participating physiotherapy clinics to be ran-
domly paired with one of the participating medical
clinics, and the remaining two medical clinics formed a
fourth and final pair. Each pair was arbitrarily given a
number from 1 to 4, and each clinic given an arbitrary
code (A or B) within each pair. These four numbered
and paired codes, without clinic identification (blinded),
were given to a researcher (TH) who generated a ran-
dom number between 0.0 and 1.0 for Clinic A in each of
the four pairs using Excel (Microsoft Corp, Redmond
WA, USA). If the number was >0.5, Clinic A was
assigned to be a Movement Biofeedback Group clinic
and its paired Clinic B to be a Guidelines-based Care
Group clinic. If the number was <0.5, the assignment
direction was the reverse. This procedure resulted in
one physician, one GP and two physiotherapists being
randomised to the intervention (movement biofeedback)
group and one physician, two GPs and one physiotherapist
being randomised to the control (guidelines-based care
only) group.
Funding
Funding for this study was equally provided by (i) a
grant from the Department of Business and Innovation
(Market Validation Program), Victorian Government,
Australia, and (ii) dorsaVi P/L (the Australian company
who manufactures the ViMove motion-sensor system
used in this study). The Department of Business and
Innovation helped in the governance of the trial. DorsaVi
supplied the motion-sensor equipment and coordinated
the trial, assisted by a contract research organisation
(Kendle P/L, Oakleigh, Victoria, Australia). All data and
trial-related documentation were independently audited by
Paul L Clark and Associates (Beaumaris Victoria, Australia).
The authors analysed the results and wrote this paper
independently of both funders, and neither funder had
any influence over how these data were presented and
the conclusions reached.
Fig. 1 Participant flow through study
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Description of treatments
All participants
All participants in this trial received advice on staying
active and general self-management of back pain. This
advice was based on the 2003 Australian National Health
and Medical Research Council guidelines for the manage-
ment of acute low back pain [13], and European guidelines
for the management of chronic non-specific LBP [14] in
the absence of similar Australian guidelines for chronic
LBP. The participants could also have received whatever
usual medical and physiotherapy care was deemed essen-
tial by their clinicians, and such guidelines-based [13, 14]
co-interventions were noted. These treatments and advice
were metered out over 6–8 sessions over a 10 week period
at the commencement of the trial.
Intervention participants
The motion-sensor biofeedback system investigated in this
research was the ViMove motion-sensor system (Version
5, dorsaVi.com). This system consists of: (i) two wireless
motion-sensors that measure three-dimensional move-
ment, movement velocity and acceleration, and orienta-
tion to gravity, (ii) two wireless surface electromyography
(EMG) sensors that measure para-spinal muscle activa-
tion, (iii) a wireless recording device (approximately the
size of a small mobile phone) that captures the sensor
data, has a button that patients can push when an event
occurs (such as an onset or increase in pain), an audio and
vibration function that can be programmed to provide
patient-specific biofeedback alerts, and (iv) a charging
dock for these wireless devices. The system also has a
comprehensive computer software application that clini-
cians use to observe movement characteristics in real-
time, to download postural and movement data from the
recording device captured during activities of daily living,
to analyse these data with the use of graphics-rich reports,
and to compare an individual’s movement pattern with
their previous assessments or with reference values.
Participants in the intervention group had an indivi-
dualised assessment including a physical examination
and biomechanical movement analysis using the ViMove
system to examine potential relationships between their
movement or posture and their pain. The ViMove was
worn both in the clinic and during the patient’s activities
of daily living. The clinician then devised a patient-
specific rehabilitation strategy designed to address any
identified deficits in the patient’s pattern of lumbo-pelvic
movement and/or posture. For example, output from
the ViMove device could be used to differentiate pelvic
tilt movement from lumbar spine flexion movement when
a participant attempted to reach towards the ground. If
movement limitation was identified and found to be
largely attributable to limited lumbar spine flexion rather
than pelvic tilt, then the lumbar spine flexion component
could be targeted for treatment. Clinicians provided ‘live
training’ in the clinic, where patients were instructed in
how to alter their movement pattern(s) or posture using
real-time on-screen biofeedback, while wearing the
ViMove device. Clinicians could also program the ViMove
to provide motion-sensor biofeedback alerts (audio ‘beeps’
and/or vibration of the wireless recording device) that
would occur during 4- to 10- h periods during which par-
ticipants wore the device at home. This biofeedback would
prompt the patient when they ‘broke a rule’ that the clin-
ician had programmed. The clinician could also prescribe
specific exercises that supplemented the patient-specific
movement biofeedback.
Control participants
Control participants received the care as described for
“all participants” which included a combination of edu-
cation and advice, exercises, imaging, manual therapy,
medication and taping/bracing as previously described
[10]. In addition, they wore the ViMove device 6 to 8
times over the 10-week treatment period to mitigate any
potential placebo effects of wearing this equipment.
Their clinicians were blocked via a software lock during
the trial to any of the motion-sensor/EMG information
collected. Patients in the control group were informed
that the ViMove system was a measurement device.
Measurements
A range of demographic data and patient outcome ques-
tionnaires, including the Fear Avoidance Beliefs Ques-
tionnaire, the Quadruple Visual Analogue Scale of pain
intensity, the Roland-Morris Disability Questionnaire,
the Patient Specific Functional Scale were collected at
baseline and periodically during the trial. These mea-
sures have previously been reported on [10].
Measurement of costs
An estimate of productivity was developed using partici-
pant self-reported industry field (18 possible codes) based
on gender-specific data provided by the Australian Bureau
of Statistics [15]. The Australian Bureau of Statistics pro-
vides mean income (based on 2015 data) for these classifi-
cations. These industry estimates were pro-rated against
the degree to which participants reported they could per-
form the duties of their occupation. An item from the Fear
Avoidance Beliefs Questionnaire was used to gauge the
degree to which back pain limited participation in their
occupation [16]. This item was worded as “I cannot do my
normal work with my present pain” and was scaled on a 0
to 6 scale with zero being “completely disagree”, three be-
ing “unsure” and six being “completely agree”.
Use of pain medications was estimated based on self-
reported medication use captured at baseline and any
change in medication use captured using the daily pain
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diary. The daily pain diary was scheduled for completion
over the first 3 months of the trial. Medications to treat
unrelated conditions (eg. heart disease) were not cap-
tured as these were assumed to have little variance over
the follow-up period from baseline attributable to the
management of back pain. Medication costs were valued
using market prices based on the Australian Pharma-
ceutical Benefits Schedule and market rates for medica-
tions that are not subsidized under this scheme.
Use of imaging and general practitioner visits for back
pain complaints were captured from participant self-report
at the 3, 6, 9 and 12 month assessments. These costs were
valued using market prices based on the Australian Medical
Benefits Schedule (eg. item 63557 is $492.80 AUD for mag-
netic resonance image of lumbar spine). Use of medical or
therapies (eg. physiotherapy, chiropractic) received for
management of low back pain in addition to the interven-
tion or control services provided were captured from par-
ticipant self-report at the 3, 6, 9 and 12 month assessments.
These services were valued using market prices based on
locally advertised rates for private practitioner services (i.e.
$77.95 AUD per visit). The use of medical services and
therapies provided as a part of the intervention and control
conditions were captured directly by project data collectors
based on attendance at treatment sessions. These services
were valued using the same local market prices ($77.95
AUD per visit). We added a cost per session for interven-
tion group participants for having access to the ViMove
system and the consumables required for its use. There is
an annual fee of $5000 AUD per year for the software li-
cense and one set of equipment. In clinical practice, it may
be feasible to use one set of equipment for up to 33 patients
per year if applied in the same manner as in the rando-
mised controlled trial (“in clinic” and “at home” monitoring
with 6–8 sessions per patient). However, for this economic
evaluation, we have conservatively estimated that one set of
equipment could be used for ~12 patients in 1 year. This
creates a “per-participant” cost of $416.67, which is ap-
proximately $60 per session if seven sessions are booked on
average. DorsaVi specific adhesives were used to attach the
motion analysis sensors and electromyography sensors in
the trial. We have conservatively added a $20 per session
cost to cover the price of adhesives and other consumables
required to apply this equipment. This resulted in a total
$80 cost per session per participant. However, electromyog-
raphy sensors may not be required for all assessments sub-
sequent to the initial assessment, which in real life would
reduce the consumables cost to ~ $9 per session.
All costs were calculated in Australian dollars ($AUD)
at 2015 values.
Measurement of outcome
The clinical outcome used for this economic evaluation
was the Patient Global Impression of Change measured at
the 12 month follow-up assessment [17]. This scale mea-
sures improvement relative to participant recall of their con-
dition at baseline on a seven-point ordinal Likert scale (Very
much improved, Much improved, Minimally improved, No
change, Minimally worse, Much worse, Very much worse).
The Patient Global Impression of Change has shown high
levels of reliability and construct validity [18, 19].
Procedure
Clinics and clinicians were recruited by staff administering
the trial. Patients were then recruited by their treating
clinicians. All participants provided written informed
consent. Participants were provided with their respective
treatments and data for the economic evaluation was col-
lected via the baseline assessment, the daily pain diaries
(first 3 months of trial) and assessments conducted with a
research assistant blinded to group allocation at 3 months,
6 months and 1 year.
Analyses
Measures of productivity and medication use for low
back pain were calculated as change scores relative to
baseline. These change scores were calculated over a
12 month follow-up time horizon using an area under
the curve approach. Only participants who completed
the final follow-up assessment (which included the only
assessment of clinical outcome measure for this eco-
nomic evaluation) were included in these analyses, mak-
ing this a form of “complete case” analysis approach. If a
participant missed a particular follow-up prior to the
12 month assessment, then the area under the curve ap-
proach was used to impute the missing data for change
scores based on the adjacent assessment points. Measures
of clinical visits and imaging for management of low back
pain were calculated as absolute values consumed over the
12 month follow-up period. No participants reported use
of hospitals or surgery for management of low back pain,
thus these costs did not affect our estimate of direct health
costs. A total cost figure was calculated for each partici-
pant, being the sum of productivity loss (or gain) over the
12 month follow-up period relative to baseline, the in-
crease (or decrease) in medication use cost over the
12 month follow-up period relative to baseline, and the
absolute cost of clinical visits outside of the trial therapy
visits, imaging, and cost of clinical visits as a part of the
trial protocol. The total cost figure was used to form the
numerators in the incremental cost effectiveness ratio.
The dichotomous measure of effect used to form the
denominator in the incremental cost effectiveness ratio
was generated by merging participants who rated them-
selves as very much improved or much improved into
one category, with all other responses being merged into
the other category. The incremental cost effectiveness
ratio was then able to be calculated as being:
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The numerator of this ratio was calculated using linear
regression analyses of the total cost variable so that the
difference between groups in their geometric mean of
the total cost variable could be calculated. We used Hu-
ber White “sandwich” variance estimators and clustered
data based on the site from which the participant was
recruited in keeping with best practice for analyses of
cluster randomised trials (so that the units of analyses
are equivalent to the units of randomisation) [20]. We
used a similar approach to calculate the difference be-
tween groups in proportion of participants who were
very or much improved according to their reported Pa-
tient Global Impression of Change. We used bootstrap
resampling to calculate a 95% confidence ellipse to visually
represent the uncertainty surrounding the incremental
cost effectiveness estimate generated [21]. We conducted
2000 replications of the original sample, based on the ori-
ginal sample size that was collected within allocated
groups. The analyses were repeated for each bootstrap
replication, and the ensuing results plotted. Cost-
effectiveness acceptability curve analyses were pursued to
identify the probability that the intervention program was
more effective and less costly from the societal perspective
than the control program [22].
Two sensitivity analyses were pursued to examine the
impact of key assumptions made for the primary ana-
lysis. First, we changed the threshold for dichotomiza-
tion of our clinical outcome, so that we now combined
those with a response of very much improved, much im-
proved, or minimally improved into the one category.
This is a justifiable sensitivity analysis to pursue as there
are no universally accepted guidelines determining how
much improvement in the Patient Global Impression of
Change scale is necessary to be clinically significant. In
the second sensitivity analysis, we excluded the cost of
providing “trial” therapy to control group participants.
This is a more controversial choice, though can be justi-
fied under the reasoning that those in the control group
may not ordinarily have pursued the amount and dur-
ation of trial therapy sessions included in this trial in a
real life context, yet still achieved the same clinical out-
come. This sensitivity analysis intentionally has the effect
of providing a more conservative estimate of the cost-
effectiveness of the intervention.
Results
There were n = 9 sites assessed for eligibility of which
eight met study inclusion criteria and were recruited
into the study. These sites recruited n = 112 participants
of whom n = 38 (intervention) and n = 45 (control)
completed the Patient Global Impression of Change at
the final assessment. These numbers are lower than the
total number who completed the final assessment in the
pilot trial as the Patient Global Impression of Change
was added to the study protocol after the first 11 pa-
tients were scheduled to have completed their 12 month
follow-up. A description of participant demographics
and their use of medication and productivity data at
baseline is presented (Table 1). Other demographics of
this sample have previously been reported [10]. The
mean (sd) change in medication use and productivity
costs, along with mean (sd) absolute costs for use of im-
aging, medical and therapy services (within the trial and
external to the trial) over the follow-up period are pre-
sented (Table 2). Three participants in the intervention
group had a total of four MRI scans of their lumbar
spine compared to six participants in the control group
each having one over the follow-up period. Thirteen par-
ticipants in the intervention group had an additional 67
therapy or medical appointments for their back pain
over the follow-up whereas twenty participants in the
control group had an additional 88 therapy or medical
appointments. We identified significant difference between
groups in term of productivity changes (intervention group
participants became more productive relative to baseline
compared to control), in the resources consumed in trial
based medical and therapy services (intervention group
consumed more) and in resources consumed in non-trial
based medical and therapy services (control group con-
sumed more). Table 2 also presents the break-down of re-
sponses to the Patient Global Impression of Change scale
across intervention and control groups where there were
significant differences in favour of the intervention group.
The incremental cost-effectiveness of the intervention
compared to the control condition for the primary ana-
lysis revealed that both total costs and clinical effects
favoured the intervention group compared to the control.
If there were 100 patients treated with the intervention, 41
more would have been ‘very much improved’ or ‘much
improved’ than had those 100 patients been provided with
the control condition. There would also have been a net
saving of $478,100. Much of this saving however was
driven by improved productivity costs. Thus it is not a
direct saving to the health care system, rather, a gain
for insurers, employers and society through participants
being able to work more after receiving intervention with
ViMove. The 95% confidence ellipse for the primary ana-
lysis revealed that the intervention dominated over the
control condition (Fig. 2). Cost-effectiveness acceptability
analysis was not pursued as the intervention dominated
Incremental cost effectiveness ¼ TotalCost InterventionGroupð Þ−TotalCost ControlGroupð Þ
%Very or Much Improved Intervention Groupð Þ−% Very or Much Improved Control Groupð Þ
ð1Þ
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over the control condition with >99% certainty. Sensitivity
analyses undertaken did not affect the conclusion of dom-
inance of the intervention condition over the control con-
dition, nor the degree of certainty of dominance of the
intervention compared to the control condition being >99%.
Discussion
This economic evaluation based on a pilot cluster rando-
mised controlled trial indicates that use of a motion-
sensor biofeedback system to augment guidelines-based
care dominates (is both more effective and less costly)
Table 2 Comparison of cost and clinical outcome measures between groups that were included in the economic evaluation
Intervention Control Regression coeff (robust 95% CI)
$AUD lost productivity (total over 12 months) $-6081 ($19, 627), $-958 ($20,364) $-5123 ($-10,174, $-72)
$AUD increase in medication use (total over 12 months) $81 ($170) $166 ($293) $-85 ($-238, $68)
$AUD absolute imaging use $52 ($191) $66 ($169) $-14 ($-125, $97)
$AUD absolute non-trial medical & therapies use $137 ($232) $170 ($285) $-53 ($-105, $-0)
$AUD absolute trial medical & therapies use $993 ($217) $516 ($71) $477 ($447, $508)
$AUD total cost (primary analysis) $-4822 ($19,667) $-40 ($20,278) $-4781 ($-9748, $186)
$AUD total cost (sensitivity analysis) $-4822 ($19,667) $-557 ($20,277) $-4265 ($-9221, $691)
Patient Global Impression of Change 8 Very much improved 2 Very much improved
15 Much improved 7 Much improved
10 Minimally improved 3 Minimally improved
5 No change 21 No change
0 Minimally worse 10 Minimally worse
0 Much worse 1 Much worse
0 Very much worse 1 Very much worse
n (%) very or much improved on Patient Global Impression of
Change (primary analysis)
23 (61%) 9 (20%) 0.41 (0.27, 0.54)
n (%) very or much or minimally improved on Patient Global
Impression of Change (sensitivity analysis)
33 (87%) 12 (26%) 0.60 (0.46, 0.74)
Data are mean (sd)
Table 1 Participant demographics and baseline data from participants who completed the 12 month assessment
Intervention Control
n 38 45
Age 39 (14) 49 (12)
Gender 18 (47%) female 26 (58%) female
Pain intensity (QVAS) (0–100 scale, mean) 61.4 (16.0) 61.0 (12.0)
Pain episode duration (weeks, median) 52 (IQR: 17.5, 62.5) 52 (IQR: 16, 364)
Fear of movement (Fear Avoidance Beliefs Questionnaire: Physical Activity subscale) (0–24 scale, mean) 14.4 (6.4) 14.2 (6.6)
Activity limitation (Patient Specific Functional Scale) (0–100 scale, mean) 3.9 (1.7) 4.4 (2.4)
Activity limitation (Roland-Morris Disability Questionnaire) (0–100 scale, mean) 52.6 (19.9) 45.6 (26.4)
$AUD medication use per day at baseline $1.03 ($0.91) $0.96 ($0.75)
$AUD weekly income estimate based on gender and industry codes $1467 ($265) $1433 ($301)
Employment industry codes
Professional, Scientific and Technical services 10 (26%) 5 (11%)
Health Care and Social Assistance 4 (11%) 10 (22%)
Agricultural, Forestry and Fishing 4 (11%) 5 (11%)
Administrative and Support services 4 (11%) 3 (7%)
Education and Training 2 (5%) 5 (11%)
Transport, Postal and Warehousing 2 (5%) 3 (7%)
Other categories 12 (32%) 14 (31%)
Data are mean (sd) or n (%) unless otherwise indicated
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compared to guidelines-based care alone. It is important
to be clear in this finding that the costs of providing the
intervention was greater than providing the control in
this study, but that the intervention group became more
productive over the 12 month follow-up period and used
fewer non-trial medical and therapy resources. This cul-
minated in an overall saving to society, estimated to be
$478,100 for every 100 patients treated to go with an
additional 41 patients being classified as much or very
much improved in relation to their low back pain. This
finding of dominance was robust to the two key sensitiv-
ity analyses undertaken, where the costs of providing
guidelines based care to the control group was elimi-
nated, and where the threshold for classifying partici-
pants as being improved or not was changed.
The finding of dominance (both being less costly and
more effective) with 95% confidence is particularly not-
able given the rarity of such a finding in this field. A re-
view of economic evaluations for guideline endorsed
interventions to reduce low back pain published in 2011
[8] included 26 studies, but identified only six studies
where the intervention was thought to “dominate” over
the control condition when considering cost-effectiveness
[23–29]. In one, the follow-up period was only 3 months
post-intervention and did not include costs of medical
services outside the trial protocol [23]. Another did not
formally undertake an incremental cost effectiveness
analysis [24, 25]. Another did not examine the 95%
confidence interval ellipse surrounding the incremental
cost-effectiveness estimate. This was important for this
study given the highly skewed cost data they reported
[26]. Of the studies that examined the 95% confidence
ellipse that surrounded the incremental cost effective-
ness estimate, none demonstrated dominance with 95%
confidence [27–29].
Some caution should be employed when using these
findings to guide clinical decision making and policy for-
mation. Data used to build this economic evaluation
were derived from a single, pilot (though of reasonable
size) randomized trial. It is the nature of “concurrent
economic evaluations” that any design-related issues or
concerns of bias or imprecision in effect size estimates
relating to the original randomized trial equally apply to
the economic evaluation. In the same way that authors
of the original trial recommended that a fully powered
trial was warranted to be clear on the effectiveness of
this intervention [10], further research is also required
to confirm the results of this economic evaluation. This
trial has demonstrated that the motion-sensor biofeed-
back approach appears to be a viable intervention from
a c
b
Fig. 2 Cost-effectiveness plane with 95% confidence ellipse for incremental cost-effectiveness estimates for the primary analysis (a), first sensitivity
analysis (b), and second sensitivity analysis (c)
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both a clinical and economic perspective, and that future
research using this approach should be a priority.
Productivity costs were a key driver of the outcome of
this economic evaluation. This was not surprising given
that productivity costs are the key driver of burden of
disease estimates in this condition [3]. Our approach to
calculating productivity was relatively indirect in that we
estimated income based on occupation and industry ra-
ther than directly capturing income from the participant.
We also estimated presenteeism by using a linear extrapo-
lation of the participants reported ability to perform their
occupation. Using indirect methods to calculate product-
ivity in economic evaluations conducted alongside clinical
trials is common [30] and is often necessary given the
threat to broader trial viability that more intensive data
collection methods for these outcomes may create. These
concerns may have introduced random error into our
productivity estimates, but as these categorisations were
undertaken by an investigator blinded to group allocation
status (KB) we do not believe this would have created a
systematic bias between groups that would have had a
substantial effect on our results or conclusions. We also
ignored the potential for productivity losses in one indi-
vidual to negatively affect co-workers’ productivity in case
of team-dependent production. The productive output of
a full team can be jeopardized by one member’s illness
[30]. This is more likely to have affected the group with
more productivity losses (the control group in our case),
which would make our cost effectiveness estimate more
conservative.
Further research in this field is clearly indicated. First,
to conduct a larger randomized trial and economic
evaluation. Second, to understand potential mechanisms
of action between the motion-sensor biofeedback inter-
vention and improved productivity. Such research should
consider whether it is purely changes in pain and function
that drive improved occupational performance, or whether
there are additional psychological benefits from wearing
the device. The function of the motion-sensor biofeedback
system to be able to alert the wearer when they remain in
a particular position for too long or if they move in a way
that may compromise their musculoskeletal health may
reassure them and make them feel as if they can perform
their work with less risk of injury. This may enhance their
willingness and motivation to participate in their occupa-
tion. Understanding potential mechanisms of action may
be useful for refining treatment protocols that optimise
the value of this approach.
Conclusion
Low back pain continues to have a major impact on oc-
cupational productivity around the world, despite years
of research to address this problem. The motion-sensor
biofeedback treatment approach investigated in this
research appears to be both more clinically effective and
economically efficient than guidelines based care alone.
This approach appears to be a viable means to manage
low back pain that may enhance productivity. Further
research in this area should be a priority as these data
have been drawn from a pilot randomised trial.
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